An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Overview[ - collapse ][ - ]
Purpose | NETU-08-18 is a clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy. |
---|---|
Condition | Chemotherapy-Induced Nausea and Vomiting |
Intervention | Drug: Netupitant and Palonosetron Drug: Palonosetron Drug: Dexamethasone |
Phase | Phase 3 |
Sponsor | Helsinn Healthcare SA |
Responsible Party | Helsinn Healthcare SA |
ClinicalTrials.gov Identifier | NCT01339260 |
First Received | April 19, 2011 |
Last Updated | September 23, 2013 |
Last verified | September 2013 |
Tracking Information[ + expand ][ + ]
First Received Date | April 19, 2011 |
---|---|
Last Updated Date | September 23, 2013 |
Start Date | April 2011 |
Estimated Primary Completion Date | Not Provided |
Current Primary Outcome Measures | Proportion of patients with complete response (CR) defined as no emesis, no rescue medication, at cycle 1 [Time Frame: 25-120 hours] [Designated as safety issue: No] |
Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
Brief Title | An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting |
---|---|
Official Title | A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy |
Brief Summary | NETU-08-18 is a clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy. |
Detailed Description | Not Provided |
Study Type | Interventional |
Study Phase | Phase 3 |
Study Design | Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention |
Condition | Chemotherapy-Induced Nausea and Vomiting |
Intervention | Drug: Netupitant and Palonosetron Drug: Palonosetron Drug: Dexamethasone |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 1455 |
Estimated Completion Date | Not Provided |
Estimated Primary Completion Date | November 2012 |
Eligibility Criteria | Inclusion Criteria: - Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be permitted. - Scheduled to receive first course of an anthracycline and cyclophosphamide containing moderately emetogenic chemotherapy (MEC) regimen for the treatment of a solid malignant tumor: cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V. doxorubicin (more or equal to 40 mg/m2) or cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V. epirubicin (more or equal to 60 mg/m2). - If scheduled to receive chemotherapy agents of minimal to low emetogenic potential they could be given on any day. - ECOG Performance Status of 0, 1, or 2. - Female patients of either non-childbearing potential or child-bearing potential with a commitment to use contraceptive methods throughout the clinical trial - Hematologic and metabolic status adequate for receiving a moderately emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance) The following inclusion criteria must be checked prior inclusion at each cycle of the Multiple-Cycle Extension: - Participation in the study during the next cycle of chemotherapy is considered appropriate by the investigator Satisfactory study compliance in the preceding cycle of chemotherapy and related study procedures. - Scheduled to receive the same chemotherapy regimen as cycle 1 - Adequate hematologic and metabolic status as defined for cycle 1 Exclusion Criteria: - If female, pregnant or lactating. - Current use of illicit drugs or current evidence of alcohol abuse. - Scheduled to receive any highly emetogenic chemotherapy (HEC) from Day 1 to Day 5 or moderately emetogenic chemotherapy (MEC) from Day 2 to Day 5 following the allowed MEC regimen. - Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1. - Any vomiting, retching, or mild nausea within 24 hours prior to Day 1. - Symptomatic primary or metastatic CNS malignancy. - Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any uncontrolled medical condition (other than malignancy) that, in the opinion of the investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks in administering the study drugs to the patient. - Known hypersensitivity or contraindication to 5-HT3 receptor antagonists or dexamethasone. - Previously received an NK1 receptor antagonist - Participation in a clinical trial involving oral netupitant administered in combination with palonosetron. - Any investigational drugs taken within 4 weeks prior to Day 1 of cycle 1, and/or is scheduled to receive any investigational drug during the study. - Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1 of cycle 1. - Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy. - Any medication with known or potential antiemetic activity within 24 hours prior to Day 1 of cycle 1 - Scheduled to receive any strong or moderate inhibitor of CYP3A4 or its intake within 1 week prior to Day 1. - Scheduled to receive any of the following CYP3A4 substrates: terfenadine, cisapride, astemizole, pimozide. - Scheduled to receive any CYP3A4 inducer or its intake within 4 weeks prior to Day 1. - History or predisposition to cardiac conduction abnormalities, except for incomplete right bundle branch block. - History of risk factors for Torsade de Point (heart failure, hypokalemia, family history of Long QT Syndrome). - Severe cardiovascular diseases, including myocardial infarction within 3 months prior to Day 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) NYHA class III-IV, and severe uncontrolled arterial hypertension. - Any illness or condition that, in the opinion of the investigator, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient. - Concurrent medical condition that would preclude administration of dexamethasone such as systemic fungal infection or uncontrolled diabetes. The following exclusion criteria must be checked prior inclusion at each cycle of the Multiple-Cycle Extension: - If female, pregnant or lactating - Active infection or uncontrolled disease except for malignancy. - Started any of the restricted medications. - Any vomiting, retching, or mild nausea within 24 hours prior to Day 1. |
Gender | Both |
Ages | 18 Years |
Accepts Healthy Volunteers | No |
Contacts | Not Provided |
Location Countries | United States, Argentina, Belarus, Brazil, Bulgaria, Croatia, Germany, Hungary, India, Italy, Mexico, Poland, Romania, Russian Federation, Ukraine |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01339260 |
---|---|
Other Study ID Numbers | NETU-08-18 |
Has Data Monitoring Committee | Yes |
Information Provided By | Helsinn Healthcare SA |
Study Sponsor | Helsinn Healthcare SA |
Collaborators | Parexel |
Investigators | Not Provided |
Verification Date | September 2013 |
Locations[ + expand ][ + ]
Anniston Oncology/Regional Medical Center | Anniston, Alabama, United States, 36207 |
---|---|
Northwest Alabama Cancer Center | Muscle Shoals, Alabama, United States, 35661 |
Genesis Cancer Centre | Hot Springs, Arkansas, United States, 71913 |
Compassionate Cancer Care Medical Group Inc | Corona, California, United States, 92879 |
Compassionate Cancer Centre Medical Group | Fountain Valley, California, United States, 92708 |
American Institute of Research | Los Angeles, California, United States, 90017 |
Facey Medical Group | Mission Hills, California, United States, 91345 |
Compassionate Cancer Care Medical Group | Riverside, California, United States, 92501 |
American Institute of Research | Whittier, California, United States, 90603 |
Denver Health and Hospital Authority | Denver, Colorado, United States, 80204 |
Palm Beach Institute of Hematology and Oncology | Boynton Beach, Florida, United States, 33435 |
Baptist Cancer Institute | Jacksonville, Florida, United States, 32207 |
Deaconess Clinic Downtown | Evansville, Indiana, United States, 47713 |
Floyd Memorial Cancer Center of Indiana | New Albany, Indiana, United States, 47150 |
Kentucky Cancer Clinic | Hazard, Kentucky, United States, 41701 |
The John R Marsh Cancer Center | Hagerstown, Maryland, United States, 21742 |
Fallon Clinic at Worcester Medical Center | Worcester, Massachusetts, United States, 01608 |
Duke University Medical Center | Durham, North Carolina, United States, 27710 |
Piedmont Hematology Oncology Associates PA | Winston-Salem, North Carolina, United States, 27103 |
Tri-County Hematology and Oncolgy Associates Inc. | Massillon, Ohio, United States, 44646 |
Signal Point Clinical Research Center LLC | Middletown, Ohio, United States, 45042 |
Charleston Hematology Oncology | Charleston, South Carolina, United States, 29414 |
Charleston Cancer Center | Charleston, South Carolina, United States, 29406 |
Wellmont Medical Associates-Oncology and Hematology | Bristol, Tennessee, United States, 37620 |
Cancer Specialists of South Texas, P.A. | Corpus Christi, Texas, United States, 78412 |
The University of Texas Health Center | Tyler, Texas, United States, 75708 |
Northern Utah Associates Hematology / Oncology | Ogden, Utah, United States, 84403 |
Northwest Medical Specialties | Tacoma, Washington, United States, 98405 |
Instituto Oncológico de Córdoba - Sanatorio Aconcagua | Cordoba, Argentina, X5006HBF |
Clínica Universitaria Reina Fabiola (Universidad Católica de Córdoba) | Córdoba, Argentina, X5004FHP |
Hospital Italiano de Cordoba | Córdoba, Argentina, 5000 |
Centro Oncológico Integral (COI) | Mar del Plata, Argentina, 7600 |
Centro Oncologico de Integracion Regional (COIR) | Mendoza, Argentina, M5500AYB |
Instituto Médico CER [Oncology] | Quilmes, Argentina, B1878DVB |
Sanatorio Parque | Rosario, Argentina, S2000DVS |
Centro Medico San Roque | San Miguel de Tucuman, Argentina, T4000AIK |
ISIS Clinica Especializada | Santa Fe, Argentina, 3000 |
Bobruisk Interregional Oncological Dispensary | Bobruisk, Belarus, 213825 |
Brest Regional Oncological Dispensary | Brest, Belarus, 224027 |
Gomel Regional Clinical Oncological Dispensary | Brest, Belarus, 246012 |
State institution N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology | Minsk, Belarus, 223040 |
Minsk city Clinical Oncological Dispensary [Oncology] | Minsk, Belarus, 220013 |
Mogilev Regional Oncological Dispensary [Oncology] | Mogilev, Belarus, 212018 |
OXION-Medicina Oncológica | Belo Horizonte, Brazil, 30150270 |
Centro de Pesquisas Clínicas em Oncologia | Cachoeiro de Itapemirim, Brazil, 29308-014 |
IPCEM - Centro de Ciências da Saúde - Universidade de Caxias | Caxias do Sul, Brazil, 95070-560 |
Hospital Araújo Jorge | Goiânia, Brazil, 74605-070 |
Clinica de Neoplasias do Litoral | ItajaÃ, Brazil, 88301-220 |
Clinica De Oncologia De Porto Alegre S S Ltda | Porto Alegre, Brazil, 90430-090 |
Hospital Moinhos de Vento | Porto Alegre, Brazil, RS90560-030 |
Instituto Ribeirãopretano de Combate ao Cancer | Ribeirão Preto, Brazil, 14015-130 |
Oncotrat Oncologia Medica Ltda [Oncology] | Rio de Janeiro, Brazil, 22451010 |
Nucleo de Oncologia da Bahia | Salvador Bahia, Brazil, 40170-110 |
Casa de Saude Santa Marcelina | São Paulo, Brazil, 08270-070 |
Hospital Santa Cruz | São Paulo, Brazil, 04121-000 |
SHATO "Sveti Mina" | Blagoevgrad, Bulgaria, 2700 |
MHAT Dr. Tota Venkova [Oncology] | Gabrovo, Bulgaria, 5300 |
Specialized Hospital for Active Treatment of Oncology | Haskovo, Bulgaria, 6300 |
UMHAT ""Dr. Georgi Stranski"" Dept. Medical Oncology | Pleven, Bulgaria, 5800 |
UMHAT "Sveti Georgi" [Clinic of Oncology and Hematology] | Plovdiv, Bulgaria, 4002 |
District Dispensery with Stationary - Sofia District | Sofia, Bulgaria, 1233 |
Specialized Hospital for Active Treatment of Onclogy Diseases - Sofia City | Sofia, Bulgaria, 1784 |
UMHAT "Tsaritsa Yoanna - ISUL" Ltd.Medical Oncology Clinic | Sofia, Bulgaria, 1527 |
Specialized Hospital for Active Treatment in Oncology | Sofia, Bulgaria, 1756 |
Complex Oncology Centre | Stara Zagora, Bulgaria, 6003 |
COC - Veliko Tarnovo Dept. Medical Oncology | Veliko Tarnovo, Bulgaria, 5000 |
Comprehensive Cancer Center - Vratsa Dept. of Palliative Care | Vratsa, Bulgaria, 3000 |
Županijska bolnica Cakovec | Cakovec, Croatia, 40000 |
Klinicki bolnicki centar Osijek [Oncology] | Osijek, Croatia, 31000 |
Opca bolnica Pula [Odjel za onklologiju] | Pula, Croatia, 52000 |
KBC Rijeka [Gastroenterology] | Rijeka, Croatia, 51000 |
Opca bolnica Varazdin [Odjel za hem.onko i klin.imun.] | Varazdin, Croatia, 42 000 |
Opca Bolnica Zadal Ulica | Zadar, Croatia, 23000 |
Klinika za tumore [Odjel za kemoter. i internisticku onkolog | Zagreb, Croatia, 10000 |
Klinički bolnički centar Zagreb [Oncology] | Zagreb, Croatia, 10 000 |
Klinicka bolnica [Sestre milosrdnice] | Zagreb, Croatia, 10000 |
Klinik und Poliklinik für Onkologie und Hämatologie Universitatsmedizin Charite Mitte | Berlin, Germany, 10117 |
Gynäkologische Arztpraxis | Berlin, Germany, 10317 |
OncoResearch Lerchenfeld UG | Hamburg, Germany, 22081 |
Schwerpktprxs gynäkolog Onkologie Prof. Dr. Diel, Dr. Gebert | Mannheim, Germany, 68161 |
Staedtisches Krankenhaus Muenchen Neuperlach | München, Germany, 81737 |
Tumorzentrum Munchen Sued - Städtisches Klinikum [Hämato-, Onkologie + Palliativmed] | München, Germany, 81545 |
Rotkreuzklinikum [München] | München, Germany, 80637 |
OncoPRO GbR Dr. R. Dengler, Dr. A. Kröber Gesellschaft für klinische Studien in der ambulanten Hämatologie und Onkologie | Regensburg, Germany, 93053 |
Universitätsklinikum Tübingen | Tübingen, Germany, 72076 |
Praxis Dr. G. Dresemann | Velen, Germany, 46342 |
Onkologische Gemeinschaftspraxis Dr. med M. Perker / PF Dr. med M. Sandherr | Weilheim, Germany, 82362 |
Semmelweis Egyetem Kútvölgyi Klinikai Tömb | Budapest, Hungary, 1125 |
Fővárosi Önkormányzat Uzsoki utcai Kórház | Budapest, Hungary, 1145 |
Petz Aladár Megyei Oktató Kórház [Onkoradiológiai Oszt | Győr, Hungary, 9024 |
Bács-Kiskun Megyei Önkormányzat Kórháza, Szegedi | Kecskemet, Hungary, 6000 |
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház | Miskolc, Hungary, 3526 |
Josa Andras Oktato Korhaz [Onkologiai Osztaly] | Nyíregyháza, Hungary, 4400 |
Pécsi Tudományegyetem Klinikai Köpont | Pécs, Hungary, 7624 |
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz | Szolnok, Hungary, 5004 |
Hemato-Oncology Clinic Ahmedabad Pvt Ltd | Ahmedabad, India, 380009 |
HCG - Multy Speciality Hospital | Ahmedabad, India, 380006 |
Sujan Surgical Cancer Hospital and Amracvati Cancer Foundation | Amravati, India, 444606 |
Sri Venkateshwara Hospital [Medical Oncology] | Bangalore, India, 560068 |
Apollo Speciality Hospital | Chennai, India, 600035 |
Dr. Kamahshi Memorial Hospital [Oncology] | Chennai, India, 600100 |
Yashoda B-Block Hospital | Hyderabad, India, 500 082 |
BIBI General Hospital & Cancer Centre [Oncology] | Hyderabad, India, 500 024 |
B.P.Poddar Hospital and Medical Research Ltd | Kolkata, India, 700053 |
Apollo Gleneagles Hospitals Kolkata | Kolkata, India, 700054 |
Shatabdhi Superspeciality Hospital | Nashik, India, 422005 |
Grant Medical Foundation - Ruby Hall Clinic | Pune, India, 411001 |
City Cancer Centre [Surgical and Medical Oncology] | Vijayawada, India, 520002 |
Fondazione Poliambulanza Istituto Ospedaliero | Brescia, Italy, 25124 |
Ospedale Vito Fazzi, ASL Lecce | Lecce, Italy, 73100 |
Presidio Ospedaliero "Alessandro Manzoni", AO Provincia di Lecco | Lecco, Italy, 23900 |
Ospedale Sacro Cuore e Don Calabria - Negrar | Negrar, Italy, 37024 |
Ospedale S.Carlo di Potenza [U.O. di Oncologia Medica] | Potenza, Italy, 85100 |
Centro Oncologico De Chihuahua | Chihuahua, Mexico, 31217 |
Centro Medico Quirurgico | Mexico, Mexico, 20234 |
Hospital de Jesus | Mexico, Mexico, 06090 |
Centro Regiomontano de Investigación Clínica | Monterrey, Mexico, 64710 |
OCA Hospital/Monterrey International Research Center | Monterrey, Mexico, 64000 |
Bialostockie Centrum Onkologii im. M.Sklodowskiej-Curie | Bialystok, Poland, 15-027 |
Wojewodzki Szpital Zespolony w Elblagu, Oddzial Onkologiczny | Elblag, Poland, 82-200 |
Niepubliczny Specjalist. Onkol. Zaklad Opieki Zdrowotnej | Koscierzyna, Poland, 83-400 |
Wojewodzki Szpital Specjalistyczny im. M.Kopernika | Lodz, Poland, 93-513 |
Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego | Lomza, Poland, 18-400 |
Olsztynski Osrodek Onkologiczny "KOPERNIK" | Olsztyn, Poland, 10-513 |
Szpital Rejonowy im. dr J. Rostka w Raciborzu | Raciborz, Poland, 47-400 |
Wojewodzki Szpital Specjalistyczny im. J. Korczaka | Slupsk, Poland, 76-200 |
Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie | Warszawa, Poland, 02-781 |
NZOZ Magodent - Centrum Medczyne Ostrobramska | Warszawa, Poland, 04-125 |
Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia-Mare [Oncologie Medicala] | Baia-Mare, Romania, 430031 |
Institutul Oncologic "Prof. Dr. Alex. Trestioreanu" [Sectia Clinica Radioterapie II] | Bucuresti, Romania, 22328 |
Spitalul Clinic CF nr.2 Bucuresti [Oncologie Medicala] | Bucuresti, Romania, 011464 |
Spitalul Universitar de Urgenta Bucuresti | Bucuresti, Romania, 050098 |
Spitalul Universitar de Urgenta Elias [Oncologie Medicala] | Bucuresti, Romania, 011461 |
Oncolab - Oncology Center Craiova | Craiova, Romania, 200385 |
Institutul Regional de Oncologia | Iasi, Romania, 700483 |
Spitalul Municipal Onesti [Sectia Oncologie Medicala] | Onesti, Romania, 601048 |
Spitalul Clinic Judetean Mures | Tg Mures, Romania, 0540142 |
Oncomed SRL | Timisoara, Romania, 300239 |
GUZ Arkhangelsk Regional Clinical Oncological Dispensary | Arkhangelsk, Russian Federation, 163045 |
Ivanovo Regional Oncological Dispensary [Chemotherapy] | Ivanovo, Russian Federation, 153013 |
GAUZ Republic Clinical Oncology Dispensary of Ministry of Health of Republic Tatarstan | Kazan, Russian Federation, 420029 |
GOU VPO Krasnoyarsk State Medical University n.a. prof. V.F. | Krasnoyarsk, Russian Federation, 660133 |
GUZ Lipetsk Regional Oncology Dispensary [General Oncology] | Lipetsk, Russian Federation, 398005 |
GUZ Regional Oncology Dispensary #2 | Magnitogorsk, Russian Federation, 455001 |
SBHI of Moscow City Oncology Clinical Hospital #62 | Moscow, Russian Federation, 143423 |
Russian Cancer Research Center | Moscow, Russian Federation, 115478 |
MBUZ City Clinical Hospital #1 | Novosibirsk, Russian Federation, 630047 |
FGBU Medical Radiology Scientific Center | Obninsk, Russian Federation, 249036 |
GUZ Perm Regional Oncology Dispensary | Perm, Russian Federation, 614066 |
GUZ Pyatigorsk Oncology Dispensary [Outpatient Department] | Pyatigorsk, Russian Federation, 357502 |
GOU VPO - Ryazan State Med. Univer. n.a. I.I.Pavlov based Ryazan Regio | Ryazan, Russian Federation, 390026 |
City Oncology Dispensary | Saint Petersburg, Russian Federation, 197022 |
St. Petersburg Clinical Oncology Dispesary - 3rd Gynecology D | Saint Petersburg, Russian Federation, 197022 |
GOU VPO Saint-Petersburg State Medical University n.a. acad. | Saint Petersburg, Russian Federation, 197022 |
GUZ "Leningrad Regional Oncology Dispensary" | Saint-Petersburg, Russian Federation, 188663 |
GUZ Samara Regional Clinical Oncology Dispensary | Samara, Russian Federation, 443031 |
FGU Research Institute of Oncology n.a. N.N.Petrov of Rosmed | St. Petersburg, Russian Federation, 197758 |
Stavropol Regional Clinical Oncology Dispensary | Stavropol, Russian Federation, 355047 |
GBUZ - Clinical Oncology Dispensary of MoH of Republic Bahkortostan | Ufa, Russian Federation, 450054 |
GUZ Republican Clinical Oncological Dispensary of public | Ufa, Russian Federation, 450054 |
Komunalnyi "Cherkaskyi oblasnyi onkolohichnyi dyspanser" Cherkaskoi oblasnoi rady, oblasnyi onkokhimioterapevtychnyi tsentr, m. Cherkasy | Cherkasy, Ukraine, 18009 |
Komunalnyi likuvalno-profilaktychnyi zaklad "Chernigivskyi | Chernigiv, Ukraine, 14029 |
Chmelnytskyi Regional Clinical Oncology Centre [Oncology] | Chmelnytskyi, Ukraine, 29009 |
Komunalnyizaklad Miska bahatoprofilna klinichna likarnia #4 | Dnipropetrovks, Ukraine, 49102 |
Donetskyi oblasnyi protypukhlynnyi tsentr | Donetsk, Ukraine, 83092 |
Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr | Kharkiv, Ukraine, 61070 |
Kyirskyi Miskyi klinichnyi onkolohichnyi tsentr | Kyiv, Ukraine, 03115 |
KZ KOR Kyivskyi oblasnyi onkologichnyi dyspanser | Kyiv, Ukraine, 04107 |
Lvivskyi derzhavnyi onkologichnyi regionalnyi likuvalno diahnostychyi tsentr | Lviv, Ukraine, 79031 |
Odeska oblasna klinichna likarnia | Odessa, Ukraine, 65025 |
Poltavskyi oblasnyi klinichnyi onkolohichnyi dyspanser Pol | Poltava, Ukraine, 36011 |
Zakarpatskyi oblasnyi klinichnyi onkodyspanser | Uzhgorod, Ukraine, 88014 |